Imagine two people with the same type of advanced stomach cancer. They both get the same strong chemotherapy to shrink their tumors before surgery. After treatment, their surgeons see the tumors have shrunk significantly.
But one patient has a hidden, higher risk. The cancer is likely still lurking in their lymph nodes.
A new study reveals a surprising way to spot that risk. It’s not just if the tumor shrinks, but how.
Stomach cancer is a major global health challenge. When it’s advanced, standard care often involves chemotherapy first. This is called neoadjuvant or conversion therapy.
The goal is to kill cancer cells and make surgery more effective.
A huge question for surgeons is: how many lymph nodes need to be removed? Lymph nodes are tiny bean-shaped organs that are part of the immune system. Cancer often spreads there first.
Removing more nodes can ensure no cancer is left behind. But it also increases the risk of complications and longer recovery.
Doctors need a better map. They need to know which patients truly need extensive lymph node removal and which might do well with less.
The Surprising Shift
Traditionally, doctors looked at how much cancer was left in the main tumor after chemo. Less cancer was considered better.
But this study looked deeper. Researchers analyzed the pattern of shrinkage in the tumor itself.
They discovered three distinct ways tumors respond. And one pattern is a remarkably clear warning sign.
How a Tumor Shrinks Tells a Story
Think of the original tumor as a weed in a garden. Chemotherapy is the weed killer.
In some patients, the weed dies from the inside out. The center withers away while the outer edges hold on. Scientists call this centripetal regression.
In others, the weed dies from the outside in. The outer edges disappear, but the core remains stubborn. This is centrifugal regression.
The third pattern is a diffuse or mixed response, with patches of death scattered throughout.
Here’s the critical link. The way the tumor shrinks appears to mirror what’s happening in the surrounding lymph nodes.
The study, published in Frontiers in Medicine, analyzed data from 195 patients with advanced stomach cancer.
The results were striking. The shrinkage pattern was a powerful predictor of cancer in the lymph nodes after chemo.
Patients with centripetal shrinkage (inside-out) had a very low risk—only about 5% had cancer in their nodes.
Patients with centrifugal shrinkage (outside-in) had a very high risk. Over 75% had cancer in their lymph nodes.
The mixed pattern fell in the middle.
Even when accounting for other factors, the tumor’s shrinkage pattern was the strongest independent clue. Adding this pattern to other clinical data significantly improved doctors' ability to predict a patient's nodal risk.
But There's a Catch.
This doesn’t mean this treatment strategy is available yet.
The analysis was done after surgery, on the tumor that was already removed. For this to guide surgery, doctors would need to identify the shrinkage pattern before or during the operation.
That’s the next big challenge.
A New Framework for the Future
The researchers are clear. Right now, this finding is most useful for post-surgery planning. It helps oncologists understand a patient’s risk level and plan the next steps, like more chemotherapy, more precisely.
But it opens a door.
“This provides a framework for future research on individualized lymphadenectomy lymph node removal,” the study suggests. The ultimate goal is to find a scan or a test that can act as a stand-in for the shrinkage pattern, giving surgeons a real-time guide.
If you or a loved one is facing stomach cancer treatment, this research is a sign of progress toward more personalized care. It is not, however, a current standard of care.
You will not be asked about your tumor’s “regression pattern” before surgery today. The study is a retrospective analysis, meaning it looked back at old data to find a new signal.
Understanding the Limits
This was a single study with a moderate number of patients. Its findings need to be confirmed by other researchers in larger groups. The most important limitation is the timing: the pattern was seen in the final pathology report, not during surgery when decisions are made.
The path forward is about translation. Scientists must now work to find a “surrogate marker”—something visible on a PET scan, MRI, or through a blood test—that can predict the shrinkage pattern before surgery.
This would then need to be tested in rigorous clinical trials. Researchers would compare outcomes between patients who had lymph node surgery guided by this marker versus standard surgery.
It’s a promising road, but a long one. This study provides a crucial new map for that journey, pointing toward a future where stomach cancer surgery is tailored not just to the disease, but to how an individual’s unique disease responds to fight back.
